PE20030859A1 - Composiciones de medicamentos sobre la base de agentes anticolinergicos y de agentes inhibidores de la cinasa del egfr - Google Patents

Composiciones de medicamentos sobre la base de agentes anticolinergicos y de agentes inhibidores de la cinasa del egfr

Info

Publication number
PE20030859A1
PE20030859A1 PE2003000163A PE2003000163A PE20030859A1 PE 20030859 A1 PE20030859 A1 PE 20030859A1 PE 2003000163 A PE2003000163 A PE 2003000163A PE 2003000163 A PE2003000163 A PE 2003000163A PE 20030859 A1 PE20030859 A1 PE 20030859A1
Authority
PE
Peru
Prior art keywords
amino
egfr
agents
etoxy
vinylcarbonyl
Prior art date
Application number
PE2003000163A
Other languages
English (en)
Inventor
Birgit Jung
Michael P Pieper
Michel Pairet
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of PE20030859A1 publication Critical patent/PE20030859A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

SE REFIERE A UN MEDICAMENTO QUE CONTIENE i)AGENTES ANTICOLINERGICOS TAL COMO SALES TIOTROPIO, OXITROPIO, IPRATROPIO EN COMBINACION CON ii)AGENTES INHIBIDORES DE CINASA DEL RECEPTOR DEL FACTOR DE CRECIMIENTO EPIDERMICO (EGFR) DE PREFERENCIA 4-[(3-CLORO-4-FLUORO-FENIL)AMINO]-7-(2-{4-(S)-(2-OXO-TETRAHIDROFURAN-5-IL)-CARBONIL]-PIPERAZIN-1-IL}-ETOXI)-6-[(VINILCARBONIL)AMINO]QUINAZOLINA; 4-[(3-CLORO-4-FLUORO-FENIL)AMINO]-7-(2-{4-(S)-(2-OXO-TETRAHIDROFURAN-5-IL)-CARBONIL]-PIPERAZIN-1-IL}-ETOXI)-6-[(VINILCARBONIL)AMINO]QUINAZOLINA; ENTRE OTROS, iii)SUSTANCIAS AUXILIARES DE PREFERENCIA MONOSACARIDOS, DISACARIDOS, POLIALCOHOLES CON UN TAMANO DE PARTICULA DE 250µm. LA RELACION DE i) A ii) ES DE 1:800 A 20:1. TAMBIEN SE REFIERE A i)UN AEROSOL PARA INHALACION CON UN CONTENIDO DE UN GAS PROPULSOR TAL COMO HIDROCARBUROS COMO N-PROPANOS, ISOBUTANO, ENTRE OTROS O HIDROCARBUROSHALOGENADOS; ii)SOLUCION O SUSPENSION PARA INHALACION DE pH ES DE 2-7 EL QUE SE AJUSTA ADICIONANDO ACIDO NITRICO, SULFURICO, ENTRE OTROS, CODISOLVENTES COMO ALCOHOL ISOPROPILICO, POLIETILENGLICOL. EL MEDICAMENTO TIENE UNA RAPIDA INICIACION DEL EFCTO ASI COO UNA DURACION DEL EFECTO PERSISTENTE
PE2003000163A 2002-02-16 2003-02-14 Composiciones de medicamentos sobre la base de agentes anticolinergicos y de agentes inhibidores de la cinasa del egfr PE20030859A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10206505A DE10206505A1 (de) 2002-02-16 2002-02-16 Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und EGFR-Kinase-Hemmern

Publications (1)

Publication Number Publication Date
PE20030859A1 true PE20030859A1 (es) 2003-11-18

Family

ID=27635037

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000163A PE20030859A1 (es) 2002-02-16 2003-02-14 Composiciones de medicamentos sobre la base de agentes anticolinergicos y de agentes inhibidores de la cinasa del egfr

Country Status (21)

Country Link
EP (1) EP1478398B1 (es)
JP (1) JP2005517039A (es)
KR (1) KR20040083519A (es)
CN (1) CN1633305A (es)
AR (1) AR038494A1 (es)
AT (1) ATE430581T1 (es)
AU (1) AU2003206881B2 (es)
BR (1) BR0307703A (es)
CA (1) CA2476127C (es)
CO (1) CO5611134A2 (es)
DE (2) DE10206505A1 (es)
ES (1) ES2326968T3 (es)
MX (1) MXPA04007813A (es)
NZ (1) NZ535166A (es)
PE (1) PE20030859A1 (es)
PL (1) PL369736A1 (es)
RU (1) RU2004127869A (es)
TW (1) TW200400036A (es)
UY (1) UY27670A1 (es)
WO (1) WO2003068264A1 (es)
ZA (1) ZA200404787B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10230751A1 (de) * 2002-07-09 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und EGFR-Kinase-Hemmern
DE102004001607A1 (de) * 2004-01-09 2005-08-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen auf der Basis von Scopin- oder Tropensäureestern mit EGFR-Kinase-Hemmern
US20060035893A1 (en) * 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
EP1957468A2 (en) * 2005-09-06 2008-08-20 T.K. Signal Ltd. Polyalkylene glycol derivatives of 4 - (phenylamino)quinazolines useful as irreversible inhibitors of epidermal growth factor receptor tyrosine kinase
KR100832594B1 (ko) 2005-11-08 2008-05-27 한미약품 주식회사 다중저해제로서의 퀴나졸린 유도체 및 이의 제조방법
CN102264745B (zh) 2008-11-10 2015-07-22 财团法人卫生研究院 作为酪胺酸激酶抑制剂的稠合双环及多环嘧啶化合物
US20120220557A1 (en) * 2011-02-17 2012-08-30 Chiesi Farmaceutici S.P.A. Liquid propellant-free formulation comprising an antimuscarinic drug
US10710968B2 (en) 2016-01-13 2020-07-14 Hadasit Medical Research Services And Development Ltd. Radiolabeled erlotinib analogs and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9622363D0 (en) * 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
DE19911509A1 (de) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10042062A1 (de) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Hertellung

Also Published As

Publication number Publication date
JP2005517039A (ja) 2005-06-09
CA2476127A1 (en) 2003-08-21
EP1478398B1 (de) 2009-05-06
EP1478398A1 (de) 2004-11-24
CN1633305A (zh) 2005-06-29
WO2003068264A1 (de) 2003-08-21
UY27670A1 (es) 2003-09-30
ATE430581T1 (de) 2009-05-15
MXPA04007813A (es) 2004-10-15
AR038494A1 (es) 2005-01-19
DE50311496D1 (de) 2009-06-18
PL369736A1 (en) 2005-05-02
AU2003206881B2 (en) 2009-02-26
CA2476127C (en) 2011-06-14
DE10206505A1 (de) 2003-08-28
TW200400036A (en) 2004-01-01
BR0307703A (pt) 2005-01-04
ES2326968T3 (es) 2009-10-22
RU2004127869A (ru) 2005-08-27
AU2003206881A1 (en) 2003-09-04
CO5611134A2 (es) 2006-02-28
ZA200404787B (en) 2005-08-11
NZ535166A (en) 2007-01-26
KR20040083519A (ko) 2004-10-02

Similar Documents

Publication Publication Date Title
ES2391563T3 (es) Formulaciones en suspensión de aerosol con TG 227 ea como agente propulsor
ES2211108T3 (es) Formulaciones farmaceuticas para aerosoles con dos o mas sustancias activas.
ATE247115T1 (de) Substituierte stickstoff-heterocyclische derivate und deren pharmazeutische verwendung
BR0313743A (pt) Benzimidazol quinolinonas e usos destas
PE20030859A1 (es) Composiciones de medicamentos sobre la base de agentes anticolinergicos y de agentes inhibidores de la cinasa del egfr
PE20081361A1 (es) Composiciones farmaceuticas de clonazepam y metodos de uso de las mismas
BR9812944A (pt) Inibidores bicìclicos da cinase
JP2023087007A (ja) ロキソプロフェンを含有してなる医薬製剤（参）
DE60308997D1 (de) Formulierungen zur inhalation
IE61562B1 (en) Azelastine-containing medicaments for application in the nose and/or on the eye
CA2559630A1 (en) Fasudil-containing preparation and method of improving stability thereof
PE20060269A1 (es) Acido 2-{[2-(2-metilaminopirimidin-4-il)-1h-indol-5-carbonil]amino}-3-(fenilpiridin-2-ilamino) propionico como inhibidor de la cinasa 1kb
ES2315541T3 (es) Formulaciones que contienen melatonina, ginkgo biloba y biotina.
JP6094388B2 (ja) ペメトレキセドを含む注射用組成物
Milne Drugs: synonyms and properties
IL157955A0 (en) Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m toluidide and pvp
SK10982002A3 (sk) Farmaceutická kompozícia obsahujúca pemetrexed spoločne s monotioglycerolom, L-cysteínom alebo kyselinou tioglykolovou
SE0103424D0 (sv) Pharmaceutical formulation
WO2002056876A2 (en) Treatment for snoring
AR050574A1 (es) Uso de un compuesto para estimulacion del crecimiento de pelo
CO4750645A1 (es) Metodo de preparacion de granulos que incorporan un medica- mento para uso farmaceutico
Kour et al. Evaluation of addition of sodium bicarbonate to dexamethasone and ropivacaine in supraclavicular brachial plexus block for upper limb orthopedic procedures
JP2017186310A (ja) エアゾール剤
CA2487716A1 (en) Pharmaceutical composition for the intranasal application containing selected cgrp antagonists derived from amino acids and process for preparing them
US8158615B2 (en) Anti-viral composition for the topical treatment of Herpes Labialis (cold sores) and method for use thereof

Legal Events

Date Code Title Description
FD Application declared void or lapsed